The total return over the past 12 months is -67.87% vs. +16.94% for the S&P 500. So far it's up -41.21% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (67.87%) | (83.22%) | (67.32%) | (52.81%) | (43.19%) | N/A |
| Total Return CAGR | (67.87%) | (83.22%) | (67.32%) | (52.81%) | (43.19%) | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
BriaCell Therapeutics Corp. (BCTX)
| Year | Start price | End price | BCTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.11 | $4.18 | (41.21%) | +14.51% | (55.72%) |
| 2025 | $84.75 | $7.11 | (91.61%) | +17.72% | (109.33%) |
| 2024 | $877.50 | $84.75 | (90.34%) | +24.89% | (115.23%) |
| 2023 | $655.50 | $877.50 | +33.87% | +26.19% | +7.68% |
| 2022 | $1,242.00 | $655.50 | (47.22%) | (18.17%) | (29.05%) |
| 2021 | $625.50 | $1,242.00 | +98.56% | +28.74% | +69.82% |
| 2020 | $1,476.00 | $625.50 | (57.62%) | +18.37% | (75.99%) |
| 2019 | $2,362.50 | $1,476.00 | (37.52%) | +31.22% | (68.74%) |
| 2018 | $4,513.50 | $2,362.50 | (47.66%) | (4.56%) | (43.10%) |
| 2017 | $6,750.00 | $4,513.50 | (33.13%) | +21.70% | (54.83%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
